Fmoc-4-Amino-1-Methylpyrrole-2-Carboxylic Acid

Pre-swollen Wang resin (100–200 mesh, loading 0.92 mmol/g) in DMF is treated with Fmoc-4-amino-1-methylpyrrole-2-carboxylic acid (4.0 equiv.), HATU (3.95 equiv.), and DIPEA (8.0 equiv.) under gentle nitrogen agitation at 25 °C on an ABI 433A peptide synthesizer. The steric bulk of the 1-methylpyrrole ring adjacent to the amine coupling site reduces acylation kinetics compared to phenylalanine derivatives; a double-coupling protocol of 45 min each is mandated when the incoming residue is also a hindered amino acid. Ninhydrin monitoring (Kaiser test) confirms completion, while a chloranil test is used for secondary amines if a proline follows. Following chain elongation, the terminal Fmoc group is removed with 20% (v/v) piperidine in DMF containing 0.1 M HOBt to minimize aspartimide formation. Final cleavage from the resin employs Reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5 v/v) for 2.5 h at room temperature. The crude peptide is precipitated in cold diethyl ether, centrifuged, and lyophilized. Reverse-phase HPLC purification on a C18 column (250 × 21.2 mm, 10 µm) using a 0.1% TFA water/acetonitrile gradient yields the target pyrrole-containing peptide at >95% purity. Compatibility constraints exist: the electron-rich pyrrole ring undergoes slow oxidative decomposition in TFA solutions containing thiol scavengers if the temperature exceeds 30 °C; reaction vessels must be shielded from direct light during cleavage to prevent chromophore darkening. Published data for long-term storage of unprotected peptides containing this residue indicate a shelf life of 6 months at −20 °C under argon, beyond which deamidation by-products become detectable by LC-MS.

Solid-Phase Peptide Synthesis Compatibility and Diketopiperazine Mitigation

Standard Fmoc-SPPS incorporating 4-amino-1-methylpyrrole-2-carboxylic acid demands specific protocol adjustments when the residue occupies the second position from the C-terminus. On dipeptidyl resin, base-mediated Fmoc removal triggers diketopiperazine (DKP) formation between the pyrrole amino group and the ester-linked C-terminal residue within 10–15 min at ambient temperature, resulting in >30% premature cleavage. This side reaction is suppressed by using a trityl-protected C-terminal amino acid on a 2-chlorotrityl chloride resin, where the steric bulk of the trityl group slows DKP cyclization. The resin is loaded at 0.6 mmol/g using Fmoc-amino acid (0.8 equiv.) and DIPEA (3.0 equiv.) in DCM for 2 h. After capping with MeOH/DIPEA (9:1 v/v), the Fmoc group on the pyrrole monomer is removed using 2% DBU in DMF containing 2% piperazine to minimize transesterification. Coupling the next residue proceeds with PyAOP (4.0 equiv.) and NMM (8.0 equiv.) in a solvent mix of NMP/DMSO (4:1 v/v) to retain the deprotected pyrrole amine in a nucleophilic state. Post-synthesis, peptides are characterized by UPLC-MS on an Acquity H-Class system equipped with a BEH C18 column (2.1 × 50 mm, 1.7 µm). The final compound is often formulated as an acetate salt via ion-exchange chromatography (Dowex 1×8 resin) to improve aqueous solubility for bioassays. Application endpoints include integrin-binding RGD mimetics where the pyrrole carboxylate serves as a bioisostere for the aspartic acid side chain.

Can 1-Methylpyrrole-2-Carboxylate Replace Histidine in Metallo-Enzyme Inhibitor Design?

The pyrrole nitrogen and the adjacent carboxylate oxygen create a bidentate metal-chelating motif that mimics the imidazole–carboxylate coordination sphere of histidine–aspartate dyads. Inhibitors of zinc-dependent matrix metalloproteinases (MMPs) have been generated by inserting Fmoc-4-amino-1-methylpyrrole-2-carboxylic acid into peptide sequences at the P1′ position. In a typical fragment-ligation approach, a resin-bound tripeptide thioester is prepared via Fmoc-SPPS with the pyrrole monomer installed as the N-terminal cap using EDC·HCl (5.0 equiv.) and HOSu (5.0 equiv.) in DMF/DCM (1:1 v/v) over 16 h at 4 °C. The thioester is then cleaved and ligated to a C-terminal hydroxamate fragment in aqueous buffer (pH 7.0, 6 M Gdn·HCl, 100 mM NaPi) using MESNa as a catalyst. The resulting hydroxamic acid derivative exhibits IC₅₀ values in the low nanomolar range against MMP-9 when assayed with a quenched fluorogenic peptide substrate (Mca-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH₂). Structural requirements from crystallographic attempts indicate that the N-methyl group on the pyrrole must be retained for optimal van der Waals contact with the S1′ pocket; the des-methyl analog loses 20-fold activity. End products are purified on a C4 preparative column (150 × 10 mm) with a gradient of 20–45% acetonitrile in 0.1% TFA, and final identity is confirmed by high-resolution Q-TOF MS within 3 ppm mass accuracy. Formulated inhibitors are stored as lyophilized TFA salts at −80 °C to prevent aggregation-driven precipitation that occurs at neutral pH in concentrations exceeding 5 µM.

Micro-scale parallel synthesis of compound libraries utilizes the Fmoc monomer in a 96-well format on a MultiPep CF system with spot-synthesized cellulose membranes. Stock solutions of the amino acid (0.3 M in NMP) are dispensed with a CyBi-SELMA robotic pipettor, and coupling is activated with DIC (3.0 equiv.) and HOBt (3.0 equiv.) directly on spots pretreated with a 15% β-alanine spacer. The small reaction volume (2.5 µL per spot) demands anhydrous solvent handling under positive argon pressure to avoid hydrolysis of the activated ester. After TFA side-chain deprotection and isopropyl ether washing, the membrane-bound arrays are screened for binding to MMP-2 using a biotinylated gelatin substrate overlay assay with streptavidin-HRP detection and chemiluminescence readout. Hits are identified at 0.05 µM threshold, and corresponding sequences are prepared on a larger scale using identical protocols scaled linearly to 0.1 mmol resin batches. Batch-to-batch variability in pyrrole oxidation state is controlled by adding 0.1 mM ascorbic acid to all aqueous buffers during the cleavage and workup steps.

When the Pyrrole Core Directs DNA Minor Groove Binding: Lexitropsin Assembly

Hairpin polyamides derived from N-methylpyrrole and N-methylimidazole amino acids bind predetermined DNA sequences with affinities comparable to transcription factors. Fmoc-4-amino-1-methylpyrrole-2-carboxylic acid serves as the pyrrole donor in solid-phase polyamide synthesis on Kaiser oxime resin (loading 0.45 mmol/g). The resin is acylated with the Fmoc-amino acid (4.0 equiv.) using HATU (4.0 equiv.) and DIEA (6.0 equiv.) for 60 min, then deprotected with 20% piperidine/DMF. A γ-aminobutyric acid turn unit is coupled using identical stoichiometry. The polyamide chain is extended iteratively, with the last coupling introducing a C-terminal β-alanine-dimethylaminopropylamide tail to enhance solubility. After stepwise assembly of an eight-ring hairpin, the crude product is cleaved with 0.5 M NaOH in 1:1 THF/MeOH at 55 °C for 4 h, neutralizing the viscous solution with glacial acetic acid. Purification on a Jupiter Proteo C12 column (250 × 4.6 mm, 4 µm) using a 0–60% acetonitrile gradient in formic acid buffer separates the full-length polyamide from deletion sequences. Final MALDI-TOF analysis with α-cyano-4-hydroxycinnamic acid matrix confirms [M+H]⁺ within 0.1% of theoretical mass. DNA thermal stabilization is measured by thermal denaturation of a matched duplex (5′-TGGTCA-3′·3′-ACCAGT-5′) at 1 µM hairpin in 10 mM sodium cacodylate, 10 mM KCl, 10 mM MgCl₂, pH 7.0, with ΔTm values exceeding 18 °C. Conjugate applications include covalent attachment of a nitrogen mustard alkylator to the C-terminus via a succinimidyl ester intermediate generated in situ with DSC and DMAP.

Orthogonal Protecting Group Strategies for Branched Polyamide Architectures

The synthesis of dendrimeric peptide structures with a pyrrole-based branching point requires simultaneous Fmoc and Alloc protection compatibility. Fmoc-4-amino-1-methylpyrrole-2-carboxylic acid is anchored to Rink amide MBHA resin (0.55 mmol/g) by its carboxyl group with HBTU/DIPEA activation. The Fmoc group is selectively removed with 2% DBU in DMF (2 × 3 min) without touching an Alloc group on a side chain. The liberated amine is then acylated with Fmoc-Lys(Alloc)-OH using PyBOP (3.0 equiv.) in the presence of 0.1 M LiCl to disrupt β-sheet aggregation. After iterative chain assembly, the Alloc group is removed with Pd(PPh₃)₄ (0.2 equiv.) and PhSiH₃ (10 equiv.) in degassed DCM under argon for 2 × 20 min, exposing multiple amine sites. Each site is functionalized with the pyrrole monomer to create a multivalent display scaffold; the pyrrole carboxylate remains protonated (pKa ~3.9) under acidic cleavage conditions, facilitating salt-free lyophilization. The resulting branched oligomers are analyzed by analytical SEC on a Superdex Peptide column in 30% acetonitrile/0.1% TFA at 0.5 mL/min. Terminal products are used as multivalent ligands for galactin-3, where the pyrrole ring is a pharmacophore replacement for lactose-derived triazoles, showing IC₅₀ values of 8–50 nM in hemagglutination inhibition assays. Scale-up to 1 mmol resin loads on an automated Liberty Blue microwave peptide synthesizer requires keeping the pyrrole monomer solution at 4 °C in the auxiliary syringe to prevent thermal oligomerization during a synthesis cycle of 4 min at 50 °C.

To construct peptide-oligonucleotide conjugates, the amino acid is employed as a linker between a phosphoramidite-synthesized DNA strand and a bioactive peptide. The pyrrole 2-carboxylate is activated with DCC/NHS in anhydrous acetonitrile, and the resulting NHS ester is isolated as a crystalline solid (mp 98–100 °C) with 92% recovered yield. This activated ester is reacted with a 5′-aminohexyl-modified oligonucleotide (10 nmol) in 0.1 M sodium borate buffer, pH 8.5, containing 30% DMSO. After 6 h at 42 °C, the crude conjugate is precipitated with 3 M sodium acetate/ethanol and desalted on a NAP-10 Sephadex column. Deprotection of the Fmoc group with 10% piperidine in H₂O/CH₃CN (1:1) proceeds without phosphodiester backbone degradation monitored by ion-pairing HPLC on a Clarity Oligo-RP column (50 × 2.1 mm, 3 µm) with hexafluoroisopropanol/triethylamine mobile phase. The exposed amine is then coupled to a cysteine-terminated hexapeptide via a disulfide bond formed with 2,2′-dipyridyl disulfide activation. Final conjugates demonstrate stable duplex formation with detected Kd values of 0.12 nM toward complementary RNA by surface plasmon resonance on a Biacore T200 using a SA chip with biotin-capture.

Solution-Phase Amidation Kinetics and the Risk of Cα-Epimerization

When constructing small-molecule libraries in solution without resin protection, amide bond formation with the free acid of Fmoc-4-amino-1-methylpyrrole-2-carboxylic acid requires careful control of electrophilic activation to prevent racemization at the electron-rich α‑carbon. The acid (1.0 equiv.) is dissolved in dry DMF containing 0.1 M and pre-cooled to 0 °C. CDI (1.1 equiv.) is added portionwise, and the mixture is stirred for 20 min to form the acyl imidazole intermediate, followed by addition of the amine component (1.05 equiv.) as its hydrochloride salt with additional DIPEA (1.1 equiv.). Under these conditions, amidation with cyclohexylamine completes within 40 min as indicated by TLC (silica gel 60 F₂₅₄, EtOAc/hexane 3:7, Rf product 0.28). L-epimer content is measured by chiral HPLC on a Chiralpak IA column (250 × 4.6 mm, 5 µm) with hexane/isopropanol/trifluoroacetic acid (90:10:0.1) at 1.0 mL/min; the detected D‑epimer is consistently below 0.8%. However, if the activation is performed with EDC alone without an auxiliary nucleophile, N-acylurea by-product formation consumes up to 15% of the starting acid. Product isolation involves washing the diluted reaction mixture with 5% citric acid, 5% NaHCO₃, and brine, drying over Na₂SO₄, and vacuum concentration. Crystallization from EtOAc/petroleum ether yields an off-white solid with >98% purity (HPLC at 215 nm). This protocol is suitable for preparing intermediates en route to pyrrole-based histone deacetylase inhibitors, where the final product must meet residual solvent limits of 800 ppm DMF as per ICH Q3C. The Fmoc group is retained until the penultimate step, then removed with diethylamine in THF for 30 min to liberate the free amine, which is immediately coupled to a heptanoic acid linker.

An alternative esterification pathway for prodrug synthesis utilizes the carboxyl group without Fmoc removal. The Fmoc-protected acid is treated with thionyl chloride (2.0 equiv.) in anhydrous DCM, generating the acid chloride, which is quenched with pivaloyloxymethyl alcohol (1.2 equiv.) in the presence of pyridine (2.5 equiv.). The resulting bis-protected ester is stable to silica gel chromatography and is globally deprotected with 20% piperidine to unmask the amine and the prodrug moiety simultaneously. In vitro plasma stability assays in rat plasma at 37 °C show a half-life of 45 min, releasing the parent acid with an absolute bioavailability improved to 34% (n=4). Published data on the metabolic fate of the 1-methylpyrrole ring in rodents, however, remain limited, and hepatocyte microsomal incubation is recommended as a prodromal clearance screen before committing to pharmacokinetic studies.